Avalyn Pharma Inc.Avalyn Pharma Inc.
AVLNHealth Care·Biotechnology
Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.
Market cap
$1.1BNo data
Revenue
No dataNo data
Net income
No dataNo data
Free cash flow
No dataNo data
Exceptional liquidity reflects a large surplus of current assets over current liabilities. Gross margin is intact while operating margin is deeply negative and all returns are negative, with ROIC substantially weaker.
As of 2026-06-30Market
Listed stock
AVLNPriceNasdaqLoading…Loading…1Y